General
Preferred name
JNJ-10191584
Synonyms
JNJ 10191584 maleate ()
VUF6002 maleate ()
JNJ 10191584 maleate salt ()
JNJ 10191584 ()
JNJ10191584 ()
VUF6002 ()
JNJ-10191584 (maleate) ()
P&D ID
PD016756
CAS
869497-75-6
73903-17-0
Tags
available
drug candidate
biased GPCR ligand
Drug indication
Discovery agent
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
124
DESCRIPTION
JNJ-10191584 is a selective, orally active antagonist of the histamine H4 receptor .
(GtoPdb)
DESCRIPTION
JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 ¦ÌM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively[1][2].
DESCRIPTION
Potent and selective sst2 agonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Selective H4 receptor antagonist; orally active
(Tocriscreen Plus)
DESCRIPTION
Selective H4 receptor antagonist; orally active
(Tocriscreen Total)
DESCRIPTION
The maleate salt form of JNJ 10191584, which has been found to be a selective histamine H4 receptor silent antagonist and could restrain mast cell and eosinophil chemotaxis in vitro.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
JNJ 10191584 maleate (VUF6002 maleate) is an orally active and selective antagonist of H4 receptor (Ki = 26 nM). JNJ 10191584 maleate inhibits chemotaxis of eosinophils and mast cells (IC50 = 530 nM and 138 nM).
(TargetMol Bioactive Compound Library)
DESCRIPTION
JNJ-10191584 is a selective histamine H4 receptor antagonist. It inhibits mast cell in vitro with IC50 value of 138nM. JNJ-10191584 has antiinflammatory and analgesic effects in animal studies of acute inflammation. No development was reported for the treatment of Allergic rhinitis, Atopic dermatitis, Pruritus and Respiratory tract disorders.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
13
Axon Medchem Screening Library
BiasDB
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
Drug Repurposing Hub
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
32
Molecular Weight
278.09
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
2
cLogP
1.6
TPSA
52.23
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Primary Target
Histamine H4 Receptors
MOA
Antagonist
Histamine Receptor antagonist
Target
HRH4
Histamine Receptor
H4 antagonist
H4 receptor
Solubility
Solubility in DMSO: ~ 19 mg/ml (or 68 mM)
Source data
